JOSE MANUEL
VALDIVIELSO REVILLA
CON
![Foto de JOSE MANUEL](/img/nophoto.png)
![Foto de Universidad Autónoma de Madrid](/img/noimage_org.png)
Universidad Autónoma de Madrid
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Universidad Autónoma de Madrid (19)
2024
-
Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men
Clinical Kidney Journal, Vol. 17, Núm. 1
2023
-
B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease
Clinical science (London, England : 1979), Vol. 137, Núm. 17, pp. 1409-1429
2021
-
Correction to: Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies (Drugs, (2021), 81, 13, (1467-1489), 10.1007/s40265-021-01555-5)
Drugs
-
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Drugs, Vol. 81, Núm. 13, pp. 1467-1489
-
Intravenous iron therapy and the cardiovascular system: risks and benefits
Clinical Kidney Journal, Vol. 14, Núm. 4, pp. 1067-1076
2020
-
IL‐17A as a potential therapeutic target for patients on peritoneal dialysis
Biomolecules, Vol. 10, Núm. 10, pp. 1-36
-
Protective role of renal proximal tubular alpha-synuclein in the pathogenesis of kidney fibrosis
Nature Communications, Vol. 11, Núm. 1
-
TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease
Journal of the American Society of Nephrology, Vol. 31, Núm. 9, pp. 2026-2042
2019
-
Atherosclerosis in chronic kidney disease: More, less, or just different?
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 39, Núm. 10, pp. 1938-1966
-
Erratum to: Lipid management in patients with chronic kidney disease (Nature Reviews Nephrology, (2018), 14, 12, (727-749), 10.1038/s41581-018-0072-9)
Nature Reviews Nephrology
-
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Nephrology Dialysis Transplantation, Vol. 34, Núm. 2, pp. 208-230
2018
-
Association of FGF-2 concentrations with atheroma progression in chronic kidney disease patients
Clinical Journal of the American Society of Nephrology, Vol. 13, Núm. 4, pp. 577-584
-
Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease
Atherosclerosis, Vol. 270, pp. 13-20
-
Epigenetic modification mechanisms involved in inflammation and fibrosis in renal pathology
Mediators of Inflammation, Vol. 2018
-
Lipid management in patients with chronic kidney disease
Nature Reviews Nephrology, Vol. 14, Núm. 12, pp. 727-749
-
Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage
Mediators of Inflammation, Vol. 2018
2015
2012
-
Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy
American Journal of Physiology - Renal Physiology, Vol. 302, Núm. 6
2011
-
Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy
Nephrology Dialysis Transplantation, Vol. 26, Núm. 6, pp. 1797-1802